A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Exclusion Criteria

• •No prior systemic treatment for metastatic NSCLC
• •High tumor tissue PD-L1 expression
• •Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
• •Adequate hematologic and end-organ function
• •For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.
• •Known mutation in the EGFR gene or an ALK fusion oncogene
• •Symptomatic, untreated, or actively progressing central nervous system metastases
• •Active or history of autoimmune disease or immune deficiency
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
• •Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• •Severe infection within 4 weeks prior to initiation of study treatment
• •Positive test result for human immunodeficiency virus (HIV)
• •Active hepatitis B or hepatitis C
• •Treatment with investigational therapy within 28 days prior to initiation of study treatment
• •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• •Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.